KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.

Cancers (Basel) · 2026 · PMC13360610 · PMID 42449583

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

In the exploratory analysis comparing survival outcomes by immunomodulatory therapy subgroup, checkpoint inhibitor recipients showed a longer median OS compared to non-checkpoint immunomodulatory therapy recipients, although this difference did not reach statistical significance (6.7 vs. 3.25 months, standard log-rank p = 0.08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.